Elevated Lgr5 expression, especially in conjunction with other early gastric cancer markers such as CD44 and CD133, has been postulated to be predictive of a particularly high risk of progression to an advanced stage of disease, i.e., low-grade dysplasia or later (Choi et al, 2016; Walker et al, 2018). The gene discussed is CD44; the disease is gastric cancer.